Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt: Research Progress and New Perspectives

doi:10.3877/cma.j.issn.2095-5782.2026.02.002

Abstract

Abstract:

The global disease burden of cirrhosis is heavy, with portal hypertension being one of the most common complications of decompensated cirrhosis, severely affecting the quality of patient survival. While relieving portal pressure, transjugular intrahepatic portosystemic shunt (TIPS) also brings enterogenous toxins into the body circulation, with a consequent rapid increase in blood ammonia levels, which induces hepatic encephalopathy, severely limiting the promotion of this technique in the clinic. This study will explore the differences between transjugular intrahepatic portosystemic shunt–associated hepatic encephalopathy (TIPS-HE) and conventional hepatic encephalopathy from the aspects of pathophysiologic mechanism, disease diagnosis and postoperative management, providing a new perspective for the precise prevention and treatment of TIPS-HE.

Key words: Transjugular Intrahepatic Portosystemic Shunt, Portal Hypertension, Hepatic encephalopathy, individualized treatment

Xinzhe Zhang, Tingting Zhao, Hui Wang, Fenna Zhang, Gong Feng, Bohan Luo, Na He. Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt: Research Progress and New Perspectives[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2026, 14(02): 135-140.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjrfsxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5782.2026.02.002

https://zhjrfsxdzzz.cma-cmc.com.cn/EN/Y2026/V14/I02/135

Figures/Tables 1

References 57

[1]	Liu YB, Chen MK. Epidemiology of liver cirrhosis and associated complications: current knowledge and future directions[J]. World J Gastroenterol, 2022, 28(41): 5910-5930.
[2]	García-Pagán JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding[J]. N Engl J Med, 2010, 362(25): 2370-2379.
[3]	Nardelli S, Riggio O, Marra F, et al. Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis[J]. J Hepatol, 2024, 80(4): 596-602.
[4]	Praktiknjo M, Abu-Omar J, Chang J, et al. Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation[J]. JHEP Rep, 2021, 3(3): 100264.
[5]	Wijdicks EF. Hepatic Encephalopathy[J]. N Engl J Med, 2016, 375(17): 1660-1670.
[6]	Labenz C, Schmidtke L, Pitton MB, et al. Ammonia levels after TIPS insertion identify patients at high risk of hepatic encephalopathy[J]. Clin Gastroenterol Hepatol, 2025, 10: S1542-3565(25)367-2.
[7]	Friis KH, Thomsen KL, Laleman W, et al. Post-transjugular intrahepatic portosystemic shunt (TIPS) hepatic encephalopathy—a review of the past decade's literature focusing on incidence, risk factors, and prophylaxis[J]. J Clin Med, 2023, 13(1): 14.
[8]	He X, Hu M, Xu Y, et al. The gut–brain axis underlying hepatic encephalopathy in liver cirrhosis[J]. Nat Med, 2025, 31(2): 627-638.
[9]	Nardelli S, Lattanzi B, Merli M, et al. Muscle alterations are associated with minimal and overt hepatic encephalopathy in patients with liver cirrhosis[J]. Hepatology, 2019, 70(5): 1704-1713.
[10]	Yin L, Chu SL, Lv WF, et al. Contributory roles of sarcopenia and myosteatosis in development of overt hepatic encephalopathy and mortality after transjugular intrahepatic portosystemic shunt[J]. World J Gastroenterol, 2023, 29(18): 2875-2887.
[11]	Liu J, Ma J, Yang C, et al. Sarcopenia in patients with cirrhosis after transjugular intrahepatic portosystemic shunt placement[J]. Radiology, 2022, 303(3): 711-719.
[12]	Rose CF, Amodio P, Bajaj JS, et al. Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy[J]. J Hepatol, 2020, 73(6): 1526-1547.
[13]	Tiede A, Stockhoff L, Liu Z, et al. Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis[J]. Clin Mol Hepatol, 2025, 31(1): 240-255.
[14]	Li J, Liu Y, Li M, et al. Association of preoperative IL-6 levels with overt HE in patients with cirrhosis after TIPS[J]. Hepatol Commun, 2023, 7(4): e0128.
[15]	Bai Y, Li K, Li X, Chen X, et al. Effects of oxidative stress on hepatic encephalopathy pathogenesis in mice[J]. Nat Commun, 2023, 14(1): 4456.
[16]	Lu K. Cellular pathogenesis of hepatic encephalopathy: an update[J]. Biomolecules, 2023, 13(2): 396.
[17]	Bobermin LD, Wartchow KM, Flores MP, et al. Ammonia-induced oxidative damage in neurons is prevented by resveratrol and lipoic acid with participation of heme oxygenase 1[J]. Neurotoxicology, 2015, 49: 28-35.
[18]	Bajaj JS. The role of microbiota in hepatic encephalopathy[J]. Gut Microbes, 2014, 5(3): 397-403.
[19]	Li M, Li K, Tang S, et al. Restoration of the gut microbiota is associated with a decreased risk of hepatic encephalopathy after TIPS[J]. JHEP Rep, 2022, 4(5): 100448.
[20]	中华医学会肝病学分会. 肝硬化肝性脑病诊疗指南(2024年版)[J]. 中华肝脏病杂志, 2024, 32(9): 799-812.
[21]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy[J]. J Hepatol, 2022, 77(3): 807-824.
[22]	Berlioux P, Robic MA, Poirson H, et al. Pre-transjugular intrahepatic portosystemic shunts (TIPS) prediction of post-TIPS overt hepatic encephalopathy: the critical flicker frequency is more accurate than psychometric tests[J]. Hepatology, 2014, 59(2): 622-629.
[23]	Ehrenbauer AF, Schneider H, Stockhoff L, et al. Predicting overt hepatic encephalopathy after TIPS: value of three minimal hepatic encephalopathy tests[J]. JHEP Rep, 2023, 5(9): 100829.
[24]	Chen X, Huang M, Yu X, et al. Hepatic-associated vascular morphological assessment to predict overt hepatic encephalopathy before TIPS: a multicenter study[J]. Hepatol Int, 2024, 18(4): 1238-1248.
[25]	Chen X, Wang T, Ji Z, et al. 3D automatic liver and spleen assessment in predicting overt hepatic encephalopathy before TIPS: a multi-center study[J]. Hepatol Int, 2023, 17(6): 1545-1556.
[26]	Wang Y, Yang L, Shang Y, et al. Identifying Minimal hepatic encephalopathy: a new perspective from magnetic resonance imaging[J]. J Magn Reson Imaging, 2025, 61(1): 11-24.
[27]	İnce O, Önder H, Gençtürk M, et al. Machine learning insights: predicting hepatic encephalopathy after TIPS placement[J]. Cardiovasc Intervent Radiol, 2023, 46(12): 1715-1725.
[28]	Ahmed Z, Farooq U, Faiza Arif S, et al. Transjugular intrahepatic portosystemic shunt outcomes in the elderly population: a systematic review and meta-analysis[J]. Gastroenterology Res, 2022, 15(6): 325-333.
[29]	Kabelitz MA, Sandmann L, Praktiknjo M, et al. Early occurrence of hepatic encephalopathy following TIPS-insertion is linked to impaired survival: a multicenter cohort study[J]. Clin Gastroenterol Hepatol, 2025, 23(12): 2214-2223. e27.
[30]	Tsai CF, Chen MH, Wang YP, et al. Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population study[J]. Gastroenterology, 2017, 152(1): 134-141.
[31]	Merola J, Chaudhary N, Qian M, et al. Hyponatremia: a risk factor for early overt encephalopathy after transjugular intrahepatic portosystemic shunt creation[J]. J Clin Med, 2014, 3(2): 359-372.
[32]	Kabelitz MA, Hartl L, Schaub G, et al. Identification of optimal portal pressure decrease to control ascites while minimizing HE after TIPS: a multicenter study[J]. Hepatology, 2025, 82(5): 1172-1186.
[33]	Lv Y, Wang Q, Luo B, et al. Identifying the optimal measurement timing and hemodynamic targets of portal pressure gradient after TIPS in patients with cirrhosis and variceal bleeding[J]. J Hepatol, 2025, 82(2): 245-257.
[34]	Wang Q, Lv Y, Bai M, et al. Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding[J]. J Hepatol, 2017, 67(3): 508-516.
[35]	Simón-Talero M, Roccarina D, Martínez J, et al. Association between portosystemic shunts and increased complications and mortality in patients with cirrhosis[J]. Gastroenterology, 2018, 154(6): 1694-1705. e4.
[36]	Vidal-González J, Quiroga S, Simón-Talero M, et al. Spontaneous portosystemic shunts in liver cirrhosis: new approaches to an old problem[J]. Ther Adv Gastroenterol, 2020, 13: 1756284820961287.
[37]	Ursic M, Ravnik D, Hribernik M, et al. Gross anatomy of the portal vein and hepatic artery ramifications in dogs: corrosion cast study[J]. Anat Histol Embryol, 2007, 36(2): 83-87.
[38]	Bai M, He CY, Qi XS, et al. Shunting branch of portal vein and stent position predict survival after transjugular intrahepatic portosystemic shunt[J]. World J Gastroenterol, 2014, 20(3): 774-785.
[39]	Luo SH, Chu JG, Huang H, et al. Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy[J]. World J Gastroenterol, 2019, 25(9): 1088-1099.
[40]	de Wit K, Schaapman JJ, Nevens F, et al. Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial)[J]. BMJ Open Gastroenterol, 2020, 7(1): e000531.
[41]	Hu Y, Zhang X, Xiao Y, et al. Efficacy and safety of rifaximin in preventing hepatic encephalopathy: a systematic review and meta-analysis[J]. PLoS One, 2025, 20(5): e0323359.
[42]	Lee EW, Eghtesad B, Garcia-Tsao G, et al. AASLD practice guidance on the use of TIPS, variceal embolization, and retrograde transvenous obliteration in the management of variceal hemorrhage[J]. Hepatology, 2024, 79(1): 224-250.
[43]	Bai M, He C, Yin Z, et al. Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS[J]. Aliment Pharmacol Ther, 2014, 40(1): 63-71.
[44]	Konstantis G, Pourzitaki C, Chourdakis M, et al. Efficacy of branched chain amino acids supplementation in liver cirrhosis: a systematic review and meta-analysis[J]. Clin Nutr, 2022, 41(6): 1171-1190.
[45]	Hassouneh R, Bajaj JS. Gut microbiota modulation and fecal transplantation: an overview on innovative strategies for hepatic encephalopathy treatment[J]. J Clin Med, 2021, 10(2): 330.
[46]	Wang Q, Lv L, Jiang H, et al. Lactobacillus helveticus R0052 alleviates liver injury by modulating gut microbiome and metabolome in D-galactosamine-treated rats[J]. Appl Microbiol Biotechnol, 2019, 103(23-24): 9673-9686.
[47]	Bloom PP, Tapper EB, Young VB, et al. Microbiome therapeutics for hepatic encephalopathy[J]. J Hepatol, 2021, 75(6): 1452-1464.
[48]	Trebicka J, Garcia-Tsao G. Controversies regarding albumin therapy in cirrhosis[J]. Hepatology, 2025, 81(1): 288-303.
[49]	Fagan A, Gavis EA, Gallagher ML, et al. A double-blind randomized placebo-controlled trial of albumin in outpatients with hepatic encephalopathy: HEAL study[J]. J Hepatol, 2023, 78(2): 312-321.
[50]	Riggio O, Nardelli S, Pasquale C, et al. No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Metab Brain Dis, 2016, 31(6): 1275-1281.
[51]	European Association for the Study of the Liver. EASL clinical practice guidelines on TIPS[J]. J Hepatol, 2025, 83(1): 177-210.
[52]	Johnson CD, Stevens CM, Bennett MR, et al. The role of vitamin D deficiency in hepatic encephalopathy: a review of pathophysiology, clinical outcomes, and therapeutic potential[J]. Nutrients, 2024, 16(23): 4007.
[53]	Diaz-Ruiz R, Poca M, Roman E, et al. Vitamin D supplementation is associated with inflammation amelioration and cognitive improvement in decompensated patients with cirrhosis[J]. Nutrients, 2025, 17(2): 226.
[54]	何创业, 陈辉, 吕勇, 等. 限流支架治疗经颈静脉肝内门体分流术后复发性或持续性显性肝性脑病的效果和安全性[J]. 临床肝胆病杂志, 2019, 35(8): 1719-1722.
[55]	Reiberger T, Hofer BS. The Baveno Ⅶ concept of cirrhosis recompensation[J]. Dig Liver Dis, 2023, 55(4): 431-441.
[56]	Villanueva C, Albillos A, Genescà J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial[J]. Lancet, 2019, 393(10181): 1597-1608.
[57]	Sánchez J, González S, Poyatos P, et al. Recompensation after TIPS reduces the incidence of hepatocellular carcinoma and increases survival in patients with cirrhosis[J]. Liver Int, 2024, 44(11): 3072-3082.

Please choose a citation manager

Content to export